VLUE vs XBI
iShares MSCI USA Value Factor ETF vs SPDR S&P Biotech ETF
- • VLUE has the lower expense ratio at 0.15% vs 0.35% for XBI.
- • VLUE pays a higher dividend yield (1.59%).
Side-by-side metrics
| Metric | VLUE | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.15% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.59% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $9.43B | $10.92B |
YTD return | 38.60% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.23 | 1.01 |
P/E ratio | 15.38 | — |
Last price | $192.71 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
VLUE top holdings
| MU | Micron Technology Inc | 20.21% |
| CSCO | Cisco Systems Inc | 4.15% |
| GM | General Motors Co | 3.89% |
| VZ | Verizon Communications Inc | 2.81% |
| T | AT&T Inc | 2.32% |
| PFE | Pfizer Inc | 1.93% |
| HPE | Hewlett Packard Enterprise Co | 1.79% |
| BAC | Bank of America Corp | 1.77% |
| F | Ford Motor Co | 1.77% |
| DIS | The Walt Disney Co | 1.75% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About VLUE
VLUE (iShares MSCI USA Value Factor ETF) is US stocks with attractive valuations vs fundamentals. Managed by iShares, the fund carries $9.4B in assets under management, an expense ratio of 0.15%, a dividend yield of 1.59%. Its largest holding is Micron Technology Inc (MU), which represents 20.2% of the portfolio. Real Estate is the fund's largest sector exposure at 1.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.